Unither Virology, a subsidiary of United Therapeutics has received a contract worth $45m from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to study antiviral drug based on its glycobiology.
The contract which spans over five years will provide a funding of $10.6m in the base period of 42 months and the remaining funds are allocated to eight milestone-based options.
The investment will support the development of drug candidate compound against dengue through preclinical safety and efficacy studies besides developing additional data against influenza.
United Therapeutics chairman and CEO Martine Rothblatt said the objective for the partnership with NIH is to develop a safe and orally available broad-spectrum antiviral drug to treat viruses such as dengue and influenza.
"Dengue is a painful mosquito-borne tropical fever suffered by millions of patients worldwide each year, and this program may help provide a path to treatment," Rothblatt added.
No comments:
Post a Comment